Fertility Preservation for Cancer Patients: A Review by Ajala, Tosin et al.
Hindawi Publishing Corporation
Obstetrics and Gynecology International
Volume 2010, Article ID 160386, 9 pages
doi:10.1155/2010/160386
Review Article
Fertility Preservation for Cancer Patients: A Review
TosinAjala,1 Junaid Raﬁ,1 PeterLarsen-Disney,2 andRichardHowell2
1Department of Obstetrics and Gynaecology, Basingstoke and North Hampshire NHS Trust, Basingstoke RG24 9NA, UK
2Department of Obstetrics and Gynaecology, Brighton and Sussex University Hospitals, Eastern Road, Brighton BN2 5BE, UK
Correspondence should be addressed to Junaid Raﬁ, drjunaidraﬁ@hotmail.com
Received 28 September 2009; Accepted 2 March 2010
Academic Editor: Howard D. Homesley
Copyright © 2010 Tosin Ajala et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Infertility can arise as a consequence of treatment of oncological conditions. The parallel and continued improvement in both the
management of oncology and fertility cases in recent times has brought to the fore-front the potential for fertility preservation
in patients being treated for cancer. Oncologists must be aware of situations where their treatment will aﬀect fertility in patients
who are being treated for cancer and they must also be aware of the pathways available for procedures such as cryopreservation of
gametes and/or embryos. Improved cancer care associated with increased cure rates and long term survival, coupled with advances
in fertility treatment means that it is now imperative that fertility preservation is considered as part of the care oﬀered to these
patients. This can only be approached within a multidisciplinary setting. There are obvious challenges that still remain to be
resolved, especially in the area of fertility preservation in prepubertal patients. These include ethical issues, such as valid consent
and research in the area of tissue retrieval, cryopreservation, and transplantation.
1.Introduction
Infertility can arise as a consequence of treatment of onco-
logical conditions. The parallel and continued improvement
in both the management of oncology and fertility cases in
recent times has brought to the fore-front the potential for
fertility preservation in patients being treated for cancer.
Infertility can arise as a consequence of treatment of
oncological conditions. The parallel and continued improve-
ment in both the management of oncology and fertility cases
in recent times has brought to the fore-front the potential
for fertility preservation in patients being treated for cancer.
With the publication of NICE Guidance on the applications
of cryopreservation in cancer treatment [1], the emphasis
on life style versus health issues within fertility care for
cancerpatientsmustshift.ClearlyOncologistsmustbeaware
of situations where their treatment will aﬀect fertility in
patients who are being treated for cancer and they must
also be aware of the pathways available for procedures such
as cryopreservation of gametes and/or embryos. The NICE
Guidance has developed on the back of a working party
from the Royal College of Physicians and the Royal College
of Radiologists, which have recommended the procedures
that are to be followed before commencing chemotherapy
and radiotherapy which are likely to aﬀect fertility; and also
the management of post treatment infertility. The British
Fertility Society has produced a strategy for developing
policy and practice in fertility preservation for survivors of
cancer [2].
It must be remembered that the NHS will currently only
fund one cycle of IVF for any woman with infertility and this
isonlyavailabletowomenwhosatisfystrictinclusioncriteria
usually including no previous children to either partner, age
between 23 to 39 years and a body mass index less than 30.
2. The Impact of Oncology Therapy on Fertility
2.1. Surgical Management. Surgery can impact on fertility in
one of two ways. It can either render someone infertile by
removal of reproductive organs or in the case of the male it
can interfere with potency or ejaculation. There is no doubt,
however, that in recent years there has been a tendency
towards more conservative treatment for many malignancies
aﬀecting the reproductive organs.
2.1.1. Female Patients. In women, there has been tendency
towards less radical approaches to cancer of the cervix with2 Obstetrics and Gynecology International
the development of loop excision techniques for very early
cervix cancer and more recently the development of the
radical trachelectomy [3, 4] which allows a radical approach
to cervix cancer that is treatable surgically, but with preser-
vation of the uterus and thus fertility. Endometrial cancer is
usually a disease of the postmenopausal group or at least in
those who have had completed their family, and therefore it
is unusual for treatment of this disease, which does involve
hysterectomy and bilateral oophorectomy, to impact upon
fertility. Epithelial ovarian cancer continues to be treated
radically with loss of reproductive organs but increasing
understanding of germ cell malignancies and borderline
tumoursoftheovaryhasledtoamoreconservativeapproach
to these neoplasms and often a single oophorectomy will be
performed where in the past, a hysterectomy and/or bilateral
oophorectomy would have been the treatment of choice. It is
unusual for vulval carcinoma to be seen in the reproductive
age group, and although it may have major psychosexual
impact it would be unusual for a surgical approach to these
to impact upon fertility.
2.1.2. Male Patients. Testicular cancer is the most prevalent
cancer aﬀecting the reproductive organs of the male, and
tendstooccuratanagewherechildbearingremainsapoten-
tial issue. The majority of these are treated with a unilateral
orchidectomy[5,6]andstagingthuspreservingreproductive
capacity. Other tumours aﬀecting the reproductive organs in
the male tend to occur in a much older age group where
fertility issues may not be of importance. Surgery for other
pelvic malignancy such as bladder, prostate, and rectum can
clearlyinterferewithpotencyorejaculation,however,theage
dependency of these tumours would suggest that most occur
inanoldergroupofpatientswherefertilityissuesareunlikely
to be of major importance. Thus fertility services are unlikely
to be as important to this older group of individuals.
3. Chemotherapy Effects on Fertility
Chemotherapy can produce signiﬁcant eﬀects upon patient
fertility. These eﬀe c t sa r ed e p e n d e n to nan u m b e ro ff a c t o r s
[7]:
(i) radical versus adjuvant chemotherapy. Radical chem-
otherapy generally has more profound eﬀects on
fertility than adjuvant chemotherapy,
(ii) single agent versus combination chemotherapy.I n -
creasing complexities of regimes are more likely to
have impacts upon fertility than single agent,
(iii) dose-dependent eﬀects. Increasing doses are likely to
have more profound eﬀects on fertility than lower
doses,
(iv) drug-dependent eﬀects.D i ﬀerent agents have a mark-
edly diﬀerent impact upon fertility with some
chemo-therapeuticagentssparingfertilitywhilstoth-
ers are extremely toxic in this regard,
(v) age-dependent eﬀects. In the female in particular,
age has a profound eﬀect on chemotherapy toxicity.
Women administered chemotherapy under the age
of 40 have a much higher chance of regaining
the normal ovarian function whilst the majority of
women over 40 administered toxic chemotherapy
will be rendered menopausal by their treatment.
Presumably part of the reason for this is the fact that
the natural attrition rate of oocyte sees a large drop
in oocyte numbers over age 40 (decreased ovarian
reserve) and this corresponds with decreased live
birth rates in fertility patients over the age of 40,
(vi) male versus female physiology. The testis in the male is
exquisitely sensitive to chemotherapy whereas, as has
already been stated, the female is variable in terms of
the tolerance to chemotherapy agents.
Detailed information regarding fertility eﬀects of many
chemotherapy regimes is lacking, but speciﬁc examples
where chemotherapy aﬀects fertility are documented include
the following.
3.1. Toxic Eﬀects of Commonly Used Chemotherapeutic Agents
on the Testis. Gonadal toxicity of the testis aﬀects sper-
matogenesis more than it does testosterone production. This
stems from the increased cyto-sensitivity of the germinal
epithelium in comparism to that of the leydig cells. The
germinal cell division is extremely high through increased
meiotic and mitotic activity thus allowing for increase
sensitivity to cytotoxic agents [8–10]. Sexual maturation of
the testis also inﬂuences the degree of gonadal damage expe-
rienced when exposed to cytotoxic drugs, the prepubertal
testis being less susceptible than post-pubertal testis [9]. The
extent to which spermatogenesis is aﬀected is inﬂuenced
by the type of cytotoxic agent(s) and the dose to which it
is exposed [8–10]. Table 1 illustrates the degree of gonadal
dysfunction of commonly used cytotoxic agents.
3.2. Toxic Eﬀects of Commonly Used Chemotherapeutic Agents
on the Ovary. A ﬁxed number of primordial follicles present
at birth form the ovarian reserve into puberty. Postpuberty
these primordial follicles contain single oocytes arrested in
the prophase of the ﬁrst meiotic division and are highly
sensitive to cytotoxic drugs leading to cellular death [11].
Follicular depletion has been shown to be physiologically
age dependent, the maximum rate of depletion occurring
around the age of 38 years when the reserve is just about
10% the number present at menarche [12]. The gonadal
toxic eﬀect is thus not just dependent on type(s) and
dosage of the cytotoxic drug(s) employed but also on the
age of the woman. Cell cycle nonspeciﬁc agents such as
cyclophosphamide (alkylating agent) will destroy resting
primordial cells as opposed to cell cycle speciﬁc agents
such as methotrexate (antimetabolite) which spare the rest
primordial cells and as such are less gonadotoxic.
(i) Adriamycin and cyclophosphamide have a 38% ovar-
ian failure rate in women aged over 40 years at 2 years
post chemotherapy.
(ii) Cyclophosphamide, Hydroxlydaunorubicin (Adriamy-
cin) Oncovin (vincristine), and Prednisolone do notObstetrics and Gynecology International 3
Table 1
Agent Known eﬀect on testis
Cyclophosphamide Severe
Nitrogen mustard Severe
Procarbazine Severe
Bleomycin Moderate
Carboplatin Moderate
Cisplatin Moderate
Cytarabine Moderate
Doxorubicin Moderate
Etoposide Moderate
Ifosfamide Moderate
Thioguanine Moderate
Vinblastine Moderate
Vincristine Moderate
Methotrexate Minimal
Eﬀects are dose dependent.
Severe = Azoospermia shortly after treatement with less than 20% recovery
of spermatogenesis.
Moderate = possible azoospermia shortly after treatment with 20–50% of
patients recovering spermatogenesis.
Minimal = possibility of transient azoospermia but more than 50% of
patients recovering spermatogenesis.
usually lead to permanent amenorrhoea in women
under 40 years of age, but may lead to early
menopause in older women.
(iii) ABVD (Doxorubicin, Bleomycin, Vincristine, and
Dacarbazine) used in the treatment of Hodgkin’s
disease is signiﬁcantly less toxic in terms of fertility
than the older MOPP (Mechlorethamine, Vincristine,
Procarbazine and Prednisolone).
(iv) Bleomycin and doxorubicin have minimal eﬀects on
fertility.
(v) Vinca alkaloids and antimetabolites have very mild
eﬀects on fertility (Methotrexate very mild at 6gm
total dose).
(vi) Taxanes a r en o tc l e a r l yd e ﬁ n e di nt e r m so ft h e i r
impact on fertility.
(vii) Cyclophosphamide, methotrexate, and 5-ﬂuorouracil
(CMF) a classical breast cancer regime will render
71% of women over 40 years of age amenorrhoeic at
2y e a r s .
4. Radiotherapy Effects on Fertility
The principle of radiotherapy is based on the ionisation of
cellular atoms and molecules leading to the destruction of
double and single DNA structures within the cell structure.
A chain of events is set up, disrupting the cell-cycle leading
to apoptosis of the cells. Radiotherapy has its use in oncology
because unlike malignant cells, most normal cells have the
inert ability to recover from the eﬀects of radiotherapy.
Clearly radiotherapy can be administered as external
beam therapy (teletherapy), or as intracavity (brachyther-
apy) treatments. In addition to this, radiotherapy can be
givenwithradicalcurativeintentorasadjuvanttherapyoften
postoperatively.
Thedirecteﬀectsofradiotherapyaredosedependentand
are also dependent on the ﬁeld applied to the individual. It is
important to consider the eﬀect of scattered radiation as well
as direct irradiation when assessing likely eﬀects on fertility.
For example, although pelvic irradiation may not directly
hit the testis in the male patient, scatter of radiotherapy will
occur from this area which may have an impact on fertility
[13, 14].
4.1. Female Patients. Radiotherapy eﬀects on the female are
dose dependant. The application of 14.3 Gray to an ovary
in a woman over 30 years of age will usually render her
irreversibly infertile and menopausal [15]. A dose of 6 Gray
to the ovary of a woman less than 30 years of age is usually
reversible,butultimately,willbringthemenopauseforwards.
Thus the female is not only concerned with issues regarding
fertility but also with hormone production, as both seem to
be equally aﬀected by radiotherapy.
Although the uterus is relatively resistant to radiotherapy
there is no doubt that uterine irradiation is harmful [16]a n d
even if fertility is conserved, uterine irradiation will result in
poor implantation [17]. This appears to be due to a number
of factors including reduced uterine volume and blood ﬂow
which have been demonstrated to result in increased mid-
trimester losses, preterm labour and intrauterine growth
retardation [18]. The vagina is relatively radio-resistant
however, irradiation of this organ carries with it the risk of
loss of lubrication and stenosis which may result in physical
impairments to fertility as well as major psychosexual issues
[19].
4.2. Male Patients. The eﬀect of radiotherapy on male
fertility is also dose dependent. The application of greater
than 6 Gray to testes will result in irreversible azoospermia.
At levels of 3.5 Gray, sterility does occur, but this is
reversible although commonly such recovery will take 18
to 24 months. Treatment age (the younger the better) and
normal pre-treatment sperm count inﬂuence the recovery
rate [20]. Fractional radiotherapy to testes for treatment of
carcinoma-insitu of the testis usually involves high doses
of radiotherapy which lead to permanent azoospermia [21–
23]. Interestingly, the Leydig cells of the testis seem far
more resistant to radiation eﬀect and therefore testosterone
production is usually less impaired in patients receiving
even relatively high dosages of radiotherapy relative to its
eﬀects on sperm production [24]. In addition, libido and
erection will usually remain normal in the male and its
sterility that is the main concern. However it is not unusual
for patients who have had pelvic irradiation to suﬀer from
erectile dysfunction as a long-term complication. This may
in part be explained by radiation induced vascular disease
leading to reduced blood ﬂow in the pelvic and penile vessels
[25].4 Obstetrics and Gynecology International
5. Fertility Preservation for
Female Cancer Patients
5.1. Options for Fertility Conservation
5.1.1. Hormone Protection by Suppressing Ovaries. GNRH
analogues have been utilised during chemotherapy to sup-
press ovarian cycling and induce a temporary medical
menopause. The action of GnRH analogues is not clearly
understood as primordial and primary follicles do not have
GnRH receptors and it is possible that GnRH analogues
preserve those follicles that have already initiated growth.
Severalstudiesinanimalshavesuggestedthatprotectionmay
be oﬀered by undertaking this manoeuvre [26], however its
beneﬁt in human therapy remains debatable. The human
studies presently available are limited in design and lack of
long-term follow-up [27]. The Option Trial (Ovarian Pro-
tection Trial in Oestrogen Non-Responsive Premenopausal
Breast Cancer Patients Receiving Adjuvant or Neo-Adjuvant
Chemotherapy) for breast cancer looked at hormone sup-
pression using GNRH analogues and progestogens and
examined the impact of this on fertility. It concluded
that using goserelin concurrently with chemotherapy is
associated with a high rate of ovarian function preservation
[28].
5.1.2. Ovarian Transposition (Oophorepexy). The aim is
to surgically remove the ovaries from the direct ﬁeld of
radiation. It is found useful during the treatment of gynae-
cological cases and haematogical cancers such as Hodgkin’s
lymphomas. Most ovarian transpositions are carried out
laparoscopically and there have been suggestions that lateral
transposition may be more protective than median transpo-
sition of the ovaries [29, 30].
5.1.3. Storage by Cryopreservation of Embryos, Oocytes, or
Ovarian Tissue. The choice of what tissue type should be
preserved depends on the type of cancer, the patient’s age,
and whether she has a partner. Often it is time however that
is the limiting factor in this choice.
5.2. Embryo Storage. E m b r y os t o r a g ei si d e a lf o ra na d u l t
woman in a stable relationship as it is an established
technique which has been available since the mid 1980s.
IVF oﬀers a success rate of approximately 30% per cycle
(dependent on age) and this is similar to the natural
conception rate that is achievable by healthy couples with-
out assisted reproductive techniques [31, 32]. It involves
stimulating the ovaries using gonadotrophins which results
in high oestrogen levels, and certainly this raises concerns
for some tumours such as breast cancers with oestrogen
receptor positivity. It is still unclear what the risks of such
techniques in terms of tumour progression or relapse in a
hormonedependentcancerare.Somegroupshaveattempted
to address this by using tamoxifen or letrozole alone or in
combination with standard IVF stimulation for women with
breast cancer [33] or endometrial cancer. Patient numbers
are small and long-term studies are currently not available.
IVF stimulation takes a minimum of two to three weeks
depending on a patient’s menstrual cycle and could be
anything up to ﬁve weeks. After stimulation of follicles
to maturation an egg collection procedure is undertaken
usually as a day case under sedation or a general anaesthetic
where vaginal ultrasound probe is used to guide transvaginal
collection of eggs. IVF is then undertaken to fertilise the
patient’s eggs with the partner’s sperm before freezing the
embryo. At present there is limited availability donor sperm
for adult women trying to preserve reproductive potential
whilst undertaking chemotherapy.
5.3. Oocyte Storage. This technique is suitable for adults and
for older teenagers who do not have a current partner. It is
important to realise that this is a new technique and success
rates are low at present with perhaps less than 5% success
r a t e sa c h i e v a b l ep e rc y c l e[ 34, 35]. Clearly this ﬁgure may
rise with improved techniques in the future but at present
less than 100 pregnancies have been documented worldwide
using this technique. The technique involves stimulation of
the ovaries, harvesting of eggs and then freezing them, which
is technically very diﬃcult. Stored eggs can later be thawed
and IVF techniques with ICSI can be used. Oocytes are much
more sensitive to damage from cryopreservation techniques
than embryos (probably secondary to spindle damage from
ice crystal formation). The formation of ice crystal and the
attendant cellular damage during freezing can potentially
be avoided by vitriﬁcation. For younger patients oocyte
storage may be an option, as harvest techniques can include
transabdominal ultrasound and laparoscopy for retrieval of
eggs rather than subjecting the patient to the transvaginal
technique.
5.4. Ovarian Tissue Storage. This is a technique that can
be used for adults and for children but it is very much
experimental at the present time. Optimal treatment beneﬁt
can only be expected in the presence of a healthy ovarian
reserve, as such it less likely to be beneﬁcial to the older
patient above 40 years. Laparoscopy is required to undertake
a biopsy of an ovary or to remove the whole ovary
for preservation. The ﬁrst case of an ovarian transplant
operation was reported in 2000 [36]. (all cases of successful
postimplantation pregnancy reported to date have utilised
the whole cortical ovarian tissue) [37]. It is therefore an
invasive procedure under general anaesthetic and carries
a mortality rate of 1 in 12,000. Tissue obtained is cut
into thin sections and then cryopreserved in a relatively
straightforward fashion. Fewer than 15 patients world-wide
have had their thawed ovarian tissue reimplanted via either
orthotopic or heterotopic transplantation. Until recently
there had been no case reported of a successful live birth
after orthotopic transplantation of cryopreserved ovarian
tissue. Donnez et al. [38] reported in The Lancet in 2004
a live birth after transplanting cryopreserved ovarian tissue
back into the pelvis of a woman following treatment for
Stage 4 non-Hodgkin’s lymphoma and Meirow et al. in 2005
[39] reported a further live birth in another young woman
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another case reported in 2005, laparoscopic cortical ovarian
transplantation was carried out between a set of 24-year-
old monozygotic twins. The recipient twin had documented
clinical premature ovarian failure. Following ovarian trans-
plantation, normal ovarian function was restored leading to
conception and delivery of a live infant at 38 weeks [40].
The risk of re-implanting tissue with occult cancer while
small remains signiﬁcant. Only patients with cancer cases
associated with low risk of ovarian metastasis such as squa-
mous cell carcinoma of the cervix, Wilm’s tumour, Hodgkin
and non-Hodgkin’s lymphoma should be considered for
future autotransplantation. Patients with moderate and in
particular high risk of ovarian involvement should not be
considered for future autotransplantation [41].
6. FertilityPreservation in
the Male Cancer Patient
Sperm cryopreservation remains the obvious choice for
males capable of producing a semen sample. This is mainly
achieved through masturbation, but can also be achieved
through testicular biopsy and testicular sperm extraction
(TESE) and epididymal aspiration of sperms to be used
for ICSI in cases of azoospermia or ductal blockage. Sperm
collection should be carried out prior to treatment to avoid
collection of potentially abnormal DNA containing cells.
Other forms of potential male fertility preserving meth-
ods such as hormonal gonadoprotection and testicular tis-
sue cryopreservation with subsequent transplantation have
eitherbeenfoundunhelpfulorstillintheexperimentalstages
[42]. Gonadal shielding is also limited in its value.
6.1. Practical Laboratory Issues for Sperm Banking. Ac r i t i c a l
factor for male patients requiring sperm banking is the
timing of the sample as it is essential that this occurs
before chemo- or radiotherapy is undertaken. Prescreening
is required and the patients are checked for Hepatitis B
and C, Syphilis, HIV and CMV. (Although positive results
will not preclude a patient from undertaking sperm storage,
a positive result will determine the batching and isolation
required for semen storage.) Appropriate paperwork is then
undertaken as required by the HFEA including the signing of
the [HFEA (006)] MS consent form to storage of sperm.
Patients are then required to attend a Reproductive
Medicine Centre to produce a semen sample (ideally this
should be three samples a few days apart). Samples are then
stored in liquid nitrogen at minus 196 degrees centigrade in
two separate locations for 10 years. Each sample undergoes
a standard diagnostic semen analysis and is assessed against
standard criteria (WHO 2000).
6.2. Long-Term Considerations. Approximately 50% of
sperm stored will be lost during the preservation and storage
process. Potential damage to cryopreserved sperm includes
osmotic injuries from cryoprotective agents, hypothermic
injury [43] and oxidative damage [44].
Most patients receive an annual letter from the Androl-
ogy Unit storing their semen to check that the patient wants
thesampletoberetainedinstorage.Forpatientstobeeligible
for semen storage they must be less than 55 years of age, they
must be able to give informed consent for storage, screening
andthefateofthesperm.Itiscertainlyfeasibletostoresperm
for many years and, at present, patients are not charged for
this facility but the issue of whether the NHS should be
formally funding this remains unanswered.
7. The Challenge for Children
Examination of the trends in Five-Year-Survival Rates for
the commonest childhood malignancies reveals sustained
improvementsincurerates.Overthetwenty-ﬁveyear-period
from 1964, the ﬁve year survival for acute lymphocytic
lymphoma has risen from close to 0% to close to 70%,
for non-Hodgkins lymphoma has risen from approximately
20% to almost 80% and for Wilms-tumour has risen from
25% to about 80% [45]. Even since that time, ﬁve-year
survivalrateshavecontinuedtoriseslowlyforthesecommon
forms of childhood malignancy. Although the challenge for
poor prognosis tumours such as neuroblastoma remains,
for other tumours the aim of the future is to sustain
improvements in cure rates and to minimise the late eﬀects
forcurabletumours.Preservationoffertilityremainsofgreat
importance intheseyoung patients andawarenessofservices
available to them may reduce the long-term morbidity of
their cancer treatment.
7.1. Young Male Patients
7.1.1. Background. T h et e s t i c l ei sr e s p o n s i b l ef o rs p e r m a t o -
genesis (the production of mature sperm). In addition to
this, it carries out steroidogenesis (the production of steroid
hormones including testosterone). Damage to the Leydig
cells of the testis results in reduced testosterone production
and an elevated luteinizing hormone levels (from the pitu-
itary gland). Damage to the germinal epithelial of the testes
results in elevated follicular stimulating hormone (FSH)
levels, low inhibin B levels and impaired spermatogenesis.
As previously discussed, a radiation dose of greater than
6 Gray to the germinal epithelium will result in permanent
azoospermia. In the prepubertal male, irradiation greater
than 20 Gray to the Leydig cells of the testis will cause
signiﬁcant damage in terms of testosterone production but
in the post-pubertal male a level of greater than 30 Gray is
required to cause this level of damage.
A study by Thomson et al. [46] examined male fer-
tility after childhood cancer (treated with radiotherapy
or chemotherapy) and examined semen analyses in long-
term cancer survivors (average of ﬁve years post treatment)
compared with controls. In the control group (untreated),
85% of subjects had a normal semen analysis, approximately
10% had poor motility and 5% had oligospermia. The
ﬁndings were quite diﬀerent in the cancer survivors group:
30% of patients had normal semen analysis, almost 30%
had poor motility, 15% had oligospermia and over 20%
had azoospermia. Of the subjects who actually produced
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produced was signiﬁcantly less than that of the control
group. An analysis of sperm DNA integrity as a measure of
quality of sperm showed no signiﬁcant diﬀerence between
the control and the cancer survivor groups. Thus, it can
be concluded that subfertility associated with previous
treatmentofchildhood cancermaybeduetoazoospermia or
oligospermia where there is a signiﬁcant reduction in sperm
concentration but normal sperm quality.
7.1.2. Strategies for Fertility Preservation in Young Males
Undergoing Treatment for Cancer. Sperm banking remains
the obvious choice for males capable of producing a semen
sample, however young males will only start producing
sperm cells suitable for cryopreservation around the age
of 12-13 years [47]. Certainly sperm retrieval should be
oﬀered to patients in whom the risk of infertility is high,
but there is now a good evidence base to suggest that if the
testicular volume is less than 10mls, it is very unlikely that
thepatientwilldemonstrateanysigniﬁcantspermatogenesis.
Thus sperm retrieval should be limited to males where
testicular volume is greater than 10mls and samples should
ideally be produced by ejaculation. In the situation where
young males are unable to ejaculate then rectal electro
stimulation [48] or testicular/epididymal [49] aspiration
may be oﬀered and can be successfully undertaken. Sperm
banking can then be done with the expectation that the
semen can be used at a later date. At present, the later use of
stored sperm is likely to require assisted conception methods
such as intracytoplasmic sperm injection (ICSI) to optimise
the likelihood of successful fertilisation [49].
7.1.3. Questions Related to Sperm Storage. An u m b e ro f
questions are raised by the opportunity to provide sperm
storage for young male cancer patients.
(1) Who exactly will need it?
(2) Who will raise the issue of sperm storage with the
patient?
(3) Where will the patient produce the sample for stor-
age?
(4) When,inrelation tohis treatment,shouldthepatient
produce a sample? Situations arise where a patient is
too ill or indeed has to be treated so acutely that there
is insuﬃcient time to oﬀer this option?
(5) Is it appropriate to discuss the issue of sperm storage
with a patient who is struggling to cope with his
diagnosis and forthcoming treatment?
(6) What is the cost of storage of sperm?
At present there is a one year audit being undertaken
of all 22 United Kingdom Children’s Cancer Study Group
(UK CCSG) centres which is Multi-Centre Research Ethics
Committee (MREC) and The Human Fertilisation and
Embryology Authority (HFEA) approved. Part one of the
studylooksatwhat,ifanything,wasdiscussedwithrespectto
infertility with the cancer patient and what risk of infertility
was given. Part two of the audit details information on
the quality of material stored, how it was obtained and
what was discussed. Results of this study should be available
next year but pilot interviews with adolescent males by
Glaser et al. [50] have revealed a number of common
themes.Patientsstronglybelievetheirchoiceisofparamount
importance and they strongly feel the need for information
relating to sperm storage. Many patients sought increased
inputonthesigniﬁcanceoffertilitypreservationandstressed
the importance of communication with professionals on
this subject. In addition to this, a common theme was that
patients felt extremely pressurised about making decisions
with respect to sperm storage in this setting.
7.2. The Legal Aspects of Fertility Preservation Young Cancer
Patients. At present in the United Kingdom, a young person
greater than 16 years of age is presumed capable of giving
valid consent for treatment and removal of gametes (under
common law) and storage and use of these gametes (gov-
erned by the HFE Act of 1990). A young person less than
16 years of age is presumed not capable of giving consent
for treatment, removal of gametes and/or storage and use
of these gametes. However, cases do exist where patients less
t h a n1 6y e a r so fa g eh a v eb e e na b l et od e m o n s t r a t ec a p a c i t y
to undertake valid consent for this, in other words Gillick
competent [51] is allowed to, in accordance with the 1990
[52]. Act as long as he is fully informed and understands
the proposed line of treatment, beneﬁts and attendant risk.
A further issue is that young people less than 16 years of age
who are not deemed competent can rely on their parents to
give consent for medical procedures that are deemed to be in
their children’s best interest. Unfortunately, parents are not
allowed to give consent for the storage and use of gametes,
and therefore there is currently no option to preserve fertility
in the prepubertal boy.
Experimentation is underway looking at the storage and
use of gonadal tissue from children [47], however this has
major ethical issues, not least of which is consent (which
is only valid if it is voluntarily obtained from an informed,
competent person). Proxy consent can be undertaken in a
therapeutic setting if it is deemed to be in the best interests
of the patient, but the question remains as to whether
removal of gonadal tissue is actually fulﬁlling this criterion.
TheHumanFertilisationandEmbryologyAuthority(HFEA)
1990 Act has jurisdiction over the storage and use of live
human gametes and embryos created in vitro, and by
deﬁnition a gamete is a “reproductive cell with a haploid
set of chromosomes that is able to take part in fertilisation
with another of the opposite sex to form a zygote”. The
implications of this Act mean that no licence is required to
store gonadal tissue from prepubertal children because they
do not contain gametes and therefore primordial follicles
in the cortical strips of ovaries (which are not considered
gametes) may be stored for girls whose parents consent
on their child’s behalf because they believe that retrieval
and storage of this tissue is in the girl’s best interests.
Unfortunatelythe samedoes not applytoboys, andalthough
boys with Tanner Stage 2 [53] or greater development may
have tissue stored in accordance with the 1990 Act if they canObstetrics and Gynecology International 7
give written informed consent, parents are not allowed on
their child’s behalf in this setting.
8.FertilityTreatment andCancer Prognosis
A concern regarding assisted reproduction techniques is
that women have to undergo hormonal manipulation, a
possible association between the use of fertility drugs and
the risk of speciﬁc cancers, this has not been convincingly
demonstrated in epidemiologic studies. With regard to
cancer risk in relation to the cause of subfertility, the
only consistent association observed is an increased risk
of endometrial cancer for women with subfertility due to
hormonal disorders. While positive ﬁndings in some studies
on fertility drugs and ovarian cancer risk have aroused
serious concern, the associations observed in most of these
reports appear to be due to bias or chance rather than being
causal [54].
The link between ovarian cancer and fertility drugs has
not been established and fertility therapy does not increase
the risk of ovarian cancer in infertile patients who already
have an increased baseline risk as a result of their infertility
[55].
However it was reported at the Society of Gynecologic
Oncologists Annual Meeting that, the long-term risk for
invasive ovarian cancer among women receiving treatment
forIVFcomparedwithsubfertilewomennottreated(relative
risk 1.51) and for borderline tumors, was increased (relative
risk 4.40). Ovarian stimulation for in vitro fertilization (IVF)
may increase the risk of ovarian malignancies, especially
borderline tumors of the ovary, according to ﬁndings from
a 15-year followup of a large Dutch cohort study [56].
9. Pregnancyand ItsEffect on
Different Cancers
The studies support a protective relationship between parity
and the incidence of ovarian cancer [57–59]. Nulliparity
increases the baseline risk twofold. Infertility appears to
increase the risk in those patients who do not subsequently
conceive [60–62].
Also in breast cancer nulliparity is associated with an
increasedriskandparityreducestherisk,althoughaSwedish
[63]andNorwegian[64]studyprovidedanevidencethatthe
risk of breast cancer is transiently increased after pregnancy
followed by subsequent decrease in risk; also early menarche
and late age at ﬁrst pregnancy are associated with increased
risk [65]. Parity (High progesterone dose in pregnancy) is a
protective whereas nulliparity and anovulatory cycles are the
risk factor for endometrial cancer.
10. Summary
Improved cancer care associated with increased cure rates
and long-term survival, coupled with advances in fertility
treatment means that it is now imperative that fertility
preservation is considered as part of the care oﬀered to these
patients. This can only be approached within a multidisci-
plinary setting. There are obvious challenges that still remain
to be resolved, especially in the area of fertility preservation
in prepubertal patients. These include ethical issues, such
as valid consent and research in the area of tissue retrieval,
cryopreservation and transplantation.
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